CY1113580T1 - Υποκατεστημενα (οξαζολιδινον-5-υλ-μεθυλ)-2-θειοφαινο-καρβοξαμιδια και χρηση αυτων στο πεδιο της πηξης του αιματος - Google Patents

Υποκατεστημενα (οξαζολιδινον-5-υλ-μεθυλ)-2-θειοφαινο-καρβοξαμιδια και χρηση αυτων στο πεδιο της πηξης του αιματος

Info

Publication number
CY1113580T1
CY1113580T1 CY20131100095T CY131100095T CY1113580T1 CY 1113580 T1 CY1113580 T1 CY 1113580T1 CY 20131100095 T CY20131100095 T CY 20131100095T CY 131100095 T CY131100095 T CY 131100095T CY 1113580 T1 CY1113580 T1 CY 1113580T1
Authority
CY
Cyprus
Prior art keywords
oxazolidinone
carboxamides
thiophene
substituted
methyl
Prior art date
Application number
CY20131100095T
Other languages
English (en)
Inventor
Swen Allerheiligen
Marcus Bauser
Dirk Heimbach
Stefan Heitmeier
Mark Jean Gnoth
Christoph Gerdes
Degenfeld Georges Von
Susanne Röhrig
Ulrich Rester
Elke Dittrich-Wengenroth
Uwe Saatmann
Adrian Tersteegen
Joachim Krüger
Holger Paulsen
Original Assignee
Bayer Intellectual Property Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39731148&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1113580(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Intellectual Property Gmbh filed Critical Bayer Intellectual Property Gmbh
Publication of CY1113580T1 publication Critical patent/CY1113580T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Η εφεύρεση αφορά νέες υποκατεστημένες οξαζολιδινόνες, μεθόδους για την παραγωγή αυτών, τη χρήση αυτών για τη θεραπευτική αγωγή ή/και για την προφύλαξη ασθενειών και τη χρήση αυτών για την παραγωγή φαρμάκων για τη θεραπευτική αγωγή ή/και για την προφύλαξη ασθενειών, συγκεκριμένα θρομβοεμβολικών διαταραχών.
CY20131100095T 2007-06-20 2013-02-01 Υποκατεστημενα (οξαζολιδινον-5-υλ-μεθυλ)-2-θειοφαινο-καρβοξαμιδια και χρηση αυτων στο πεδιο της πηξης του αιματος CY1113580T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007028319A DE102007028319A1 (de) 2007-06-20 2007-06-20 Substituierte Oxazolidinone und ihre Verwendung
EP08773372A EP2170877B1 (de) 2007-06-20 2008-06-07 Substituierte (oxazolidinon-5-yl-methyl) -2-thiophen-carboxamide und ihre verwendung im gebiet der blutgerinnung

Publications (1)

Publication Number Publication Date
CY1113580T1 true CY1113580T1 (el) 2016-06-22

Family

ID=39731148

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100095T CY1113580T1 (el) 2007-06-20 2013-02-01 Υποκατεστημενα (οξαζολιδινον-5-υλ-μεθυλ)-2-θειοφαινο-καρβοξαμιδια και χρηση αυτων στο πεδιο της πηξης του αιματος

Country Status (43)

Country Link
US (2) US8383822B2 (el)
EP (1) EP2170877B1 (el)
JP (1) JP5537421B2 (el)
KR (1) KR101535312B1 (el)
CN (1) CN101821259B (el)
AR (2) AR066981A1 (el)
AU (1) AU2008266525B8 (el)
BR (1) BRPI0813736A2 (el)
CA (1) CA2692166C (el)
CL (1) CL2008001691A1 (el)
CO (1) CO6251281A2 (el)
CR (1) CR11168A (el)
CU (1) CU23820A3 (el)
CY (1) CY1113580T1 (el)
DE (1) DE102007028319A1 (el)
DK (1) DK2170877T5 (el)
DO (1) DOP2009000285A (el)
EC (1) ECSP099807A (el)
ES (1) ES2397799T3 (el)
GT (1) GT200900319A (el)
HK (1) HK1147991A1 (el)
HN (1) HN2009003424A (el)
HR (1) HRP20130072T1 (el)
IL (1) IL202351A (el)
JO (1) JO2798B1 (el)
MA (1) MA31535B1 (el)
MX (1) MX2009013711A (el)
MY (1) MY150931A (el)
NZ (1) NZ581540A (el)
PA (1) PA8784301A1 (el)
PE (1) PE20090332A1 (el)
PL (1) PL2170877T3 (el)
PT (1) PT2170877E (el)
RS (1) RS52639B (el)
RU (1) RU2481345C2 (el)
SG (1) SG182220A1 (el)
SI (1) SI2170877T1 (el)
SV (1) SV2009003435A (el)
TN (1) TN2009000503A1 (el)
TW (1) TWI413642B (el)
UA (1) UA98793C2 (el)
UY (1) UY31133A1 (el)
WO (1) WO2008155032A1 (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006039589A1 (de) * 2006-08-24 2008-03-06 Bayer Healthcare Ag Aminoacyl-Prodrugs II
DE102007028319A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028407A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102010028362A1 (de) * 2010-04-29 2011-11-03 Bayer Schering Pharma Aktiengesellschaft Herstellverfahren
CN102464658B (zh) * 2010-11-03 2014-04-16 天津药物研究院 噁唑烷酮衍生物及其制备方法和用途
US20140050743A1 (en) 2011-01-19 2014-02-20 Bayer Intellectual Property Gmbh Binding proteins to inhibitors of coagulation factors
CN103626749A (zh) * 2012-08-21 2014-03-12 苏州泽璟生物制药有限公司 取代的噁唑烷酮化合物和包含该化合物的药物组合物及其用途
WO2014183667A1 (zh) * 2013-05-17 2014-11-20 天津药物研究院 一种噁唑烷酮衍生物的乙酸溶剂化物及其制备方法和用途
CN103242307B (zh) * 2013-05-17 2015-08-12 天津药物研究院有限公司 一种噁唑烷酮类衍生物晶型ⅰ及其制备方法和用途
CN103232446B (zh) * 2013-05-17 2015-09-23 天津药物研究院 一种噁唑烷酮衍生物晶型ⅱ及其制备方法和用途

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
DE4319041A1 (de) 1992-10-23 1994-04-28 Bayer Ag Trisubstituierte Biphenyle
EP1686127A1 (de) 1996-10-14 2006-08-02 Bayer HealthCare AG Neue Heterocyclylmethyl-substituierte Pyrazolderivate und ihre Verwendung zur Behandlung von Herz-Kreislauf-Erkrankungen
DE19642255A1 (de) 1996-10-14 1998-04-16 Bayer Ag Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
DE19649460A1 (de) 1996-11-26 1998-05-28 Bayer Ag Neue substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834045A1 (de) 1998-07-29 2000-02-03 Bayer Ag (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19846514A1 (de) 1998-10-09 2000-04-20 Bayer Ag Neue Heterocyclyl-methyl-substituierte Pyrazole
US6259067B1 (en) 1998-10-16 2001-07-10 Medical Solutions, Inc. Temperature control system and method for heating and maintaining medical items at desired temperatures
DE19920352A1 (de) 1999-05-04 2000-11-09 Bayer Ag Substituiertes Pyrazolderivat
EP1192132B1 (en) 1999-06-14 2005-09-07 Eli Lilly And Company Serine protease inhibitors
DE19942809A1 (de) 1999-09-08 2001-03-15 Bayer Ag Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
IL150348A0 (en) * 1999-12-21 2002-12-01 Upjohn Co Oxazolidinones having a sulfoximine functionality and their use as antimicrobial agents
DE19962924A1 (de) * 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
GB0114004D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0114005D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
TWI257389B (en) 2001-06-12 2006-07-01 Lilly Co Eli Pharmaceutical compound
WO2003000657A1 (fr) 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Derives de diamine
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
EP1451164A2 (en) * 2001-07-12 2004-09-01 PHARMACIA & UPJOHN COMPANY Amide derivatives having improved solubility
RU2345993C2 (ru) 2001-09-21 2009-02-10 Бристол-Маерс Сквибб Компани ЛАКТАМСОДЕРЖАЩЕЕ СОЕДИНЕНИЕ И ЕГО ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Xa
TW200303201A (en) 2001-12-10 2003-09-01 Bristol Myers Squibb Co Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones
PE20040804A1 (es) 2002-12-19 2004-12-31 Boehringer Ingelheim Pharma DERIVADOS DE CARBOXAMIDAS COMO INHIBIDORES DEL FACTOR Xa
US7205318B2 (en) 2003-03-18 2007-04-17 Bristol-Myers Squibb Company Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors
DE10322469A1 (de) 2003-05-19 2004-12-16 Bayer Healthcare Ag Heterocyclische Verbindungen
US7265140B2 (en) * 2003-09-23 2007-09-04 Pfizer Inc Acyloxymethylcarbamate prodrugs of oxazolidinones
EP1683800A4 (en) 2003-11-12 2010-08-25 Daiichi Sankyo Co Ltd PROCESS FOR PRODUCING THIAZOLE DERIVATIVE
DE10355461A1 (de) * 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
JP2005179272A (ja) 2003-12-19 2005-07-07 Yamanouchi Pharmaceut Co Ltd カルボキサミド誘導体のマロン酸塩結晶
DE102004002044A1 (de) * 2004-01-15 2005-08-04 Bayer Healthcare Ag Herstellverfahren
GB0405272D0 (en) 2004-03-09 2004-04-21 Trigen Ltd Compounds
AU2005257999B2 (en) 2004-06-18 2011-12-08 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
US20060069260A1 (en) * 2004-09-28 2006-03-30 Huiping Zhang Preparation of N-aryl pyridones
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
US20090076015A1 (en) 2005-03-31 2009-03-19 Hidemitsu Nishida Tricyclic Spiro Compound Comprising Acyl Group Bound to Nitrogen Atom in the Ring
US20080221063A1 (en) 2005-07-08 2008-09-11 Astrazeneca Ab Heterocyclic Sulfonamide Derivatives As Inhibitors Of Factor Xa
AR057976A1 (es) * 2005-08-29 2008-01-09 Boehringer Ingelheim Int Biarilos sustituidos y su uso como medicamentos.
DE102005047558A1 (de) * 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
DE102005050498A1 (de) 2005-10-21 2007-06-06 Bayer Healthcare Aktiengesellschaft Cyclopropylessigsäure-Derivate und ihre Verwendung
DE102005050375A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Tetrazol-Derivate und ihre Verwendung
DE102005050376A1 (de) 2005-10-21 2007-05-31 Bayer Healthcare Ag Dicarbonsäure-Derivate und ihre Verwendung
DE102005050377A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Heterocyclische Verbindungen und ihre Verwendung
DE102005050497A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Difluorphenol-Derivate und ihre Verwendung
DE102006025314A1 (de) * 2006-05-31 2007-12-06 Bayer Healthcare Ag Arylsubstituierte Heterozyklen und ihre Verwendung
DE102006039589A1 (de) * 2006-08-24 2008-03-06 Bayer Healthcare Ag Aminoacyl-Prodrugs II
DE102007028407A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028406A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028319A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung

Also Published As

Publication number Publication date
KR101535312B1 (ko) 2015-07-09
HRP20130072T1 (hr) 2013-02-28
CA2692166A1 (en) 2008-12-24
NZ581540A (en) 2012-01-12
CU23820A3 (es) 2012-06-21
GT200900319A (es) 2011-11-09
JP2010530383A (ja) 2010-09-09
UY31133A1 (es) 2009-01-30
ECSP099807A (es) 2010-01-29
SG182220A1 (en) 2012-07-30
DK2170877T3 (da) 2013-02-11
RU2481345C2 (ru) 2013-05-10
SV2009003435A (es) 2010-08-23
MX2009013711A (es) 2010-02-01
US8383822B2 (en) 2013-02-26
PL2170877T3 (pl) 2013-03-29
UA98793C2 (ru) 2012-06-25
DE102007028319A1 (de) 2008-12-24
RS52639B (en) 2013-06-28
HK1147991A1 (en) 2011-08-26
AU2008266525B2 (en) 2013-09-05
ES2397799T3 (es) 2013-03-11
BRPI0813736A2 (pt) 2014-12-30
CR11168A (es) 2010-06-28
US8846934B2 (en) 2014-09-30
EP2170877B1 (de) 2012-11-21
EP2170877A1 (de) 2010-04-07
AR066981A1 (es) 2009-09-23
WO2008155032A1 (de) 2008-12-24
US20100184740A1 (en) 2010-07-22
CL2008001691A1 (es) 2008-12-26
JO2798B1 (en) 2014-03-15
CU20090216A7 (es) 2011-10-14
MA31535B1 (fr) 2010-07-01
CA2692166C (en) 2015-01-27
KR20100021615A (ko) 2010-02-25
AU2008266525A1 (en) 2008-12-24
JP5537421B2 (ja) 2014-07-02
HN2009003424A (es) 2012-01-05
TWI413642B (zh) 2013-11-01
MY150931A (en) 2014-03-14
US20140057951A1 (en) 2014-02-27
CO6251281A2 (es) 2011-02-21
PE20090332A1 (es) 2009-04-09
PA8784301A1 (es) 2009-02-09
SI2170877T1 (sl) 2013-03-29
CN101821259A (zh) 2010-09-01
IL202351A0 (en) 2010-06-30
PT2170877E (pt) 2013-01-28
TN2009000503A1 (en) 2011-03-31
DK2170877T5 (da) 2013-03-04
CN101821259B (zh) 2013-10-30
IL202351A (en) 2015-10-29
DOP2009000285A (es) 2010-01-31
TW200911797A (en) 2009-03-16
RU2010101307A (ru) 2011-07-27
AU2008266525B8 (en) 2013-09-19
AR067057A1 (es) 2009-09-30

Similar Documents

Publication Publication Date Title
CY1113580T1 (el) Υποκατεστημενα (οξαζολιδινον-5-υλ-μεθυλ)-2-θειοφαινο-καρβοξαμιδια και χρηση αυτων στο πεδιο της πηξης του αιματος
CY1117372T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες και η χρηση τους
CY1119123T1 (el) Δις-αρυλοσυζευγμενες αρυλοτριαζολονες και η χρηση τους
CY1121318T1 (el) Συμπλοκα λιποπρωτεϊνων και παρασκευη και χρησεις αυτων
CY1123996T1 (el) Υποκατεστημενα παραγωγα οξοπυριδινης
CY1116455T1 (el) Υποκατεστημενα 4-αρυλο-1,4-διυδρο-1,6-ναφθυριδιν αμιδια και η χρηση τους
ATE537168T1 (de) Substituierte oxazolidinone und ihre verwendung
CY1118588T1 (el) Νεα 5-αμινοτετραϋδροκινολινο-2-καρβοξυλικα οξεα και η χρηση τους
CY1117183T1 (el) Διακλαδισμενα παραγωγα 3-φαινυλοπροπιονικου οξεος και η χρηση τους
CY1119840T1 (el) Δικυκλικως υποκατεστημενες ουρακιλες και η χρηση αυτων
CY1117123T1 (el) Παραγωγα οιστρα-1,3,5(10),16-τετραενο-3- καρβοξαμιδιου, μεθοδοι για την παραγωγη αυτων, φαρμακευτικα παρασκευασματα που τα περιεχουν καθως και η χρηση αυτων για την παραγωγη φαρμακευτικων μεσων
CY1112813T1 (el) 4-(4-κυανο-2-θειοαρυλ)διϋδροπυριμιδινονες και η χρηση αυτων
ATE453642T1 (de) Substituierte phenylaminopyrimidine
CY1116234T1 (el) Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
CY1114760T1 (el) Θεραπευτικη αγωγη αθηροσκληρωσης
ATE475651T1 (de) Aryl-substituierte heterozyklen und ihre verwendung
ATE433459T1 (de) Desoxo-nonadepsipeptide
ATE455789T1 (de) Substituierte nonadepsipeptide
ATE410443T1 (de) Heterocyclyl-substituierte nonadepsipeptide
MX2009013709A (es) (oxazolidinon-5-ilmetil)-2-tiofenocarboxamidas sustituidas y su uso en el campo de la coagulación sanguínea.
ATE524488T1 (de) Lysobactinamide
CY1117577T1 (el) Υποκατεστημενα φουρανοκαρβοξαμιδια και χρηση αυτων
DOP2010000156A (es) Oxazolidinonas para el tratamiento y/o profilaxis de la insuficiencia cardiaca
EA201501176A1 (ru) Замещенные бензоксазолы